MacroGenics’ (MGNX) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of MacroGenics (NASDAQ:MGNX) in a research note released on Monday,Benzinga reports. The brokerage currently has a $2.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MacroGenics’ Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.78) EPS and FY2026 earnings at ($3.01) EPS.

Other research analysts have also recently issued research reports about the company. Leerink Partners dropped their price target on MacroGenics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Friday, August 15th. Wall Street Zen lowered MacroGenics from a “hold” rating to a “sell” rating in a report on Saturday, August 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MacroGenics in a research report on Wednesday, October 8th. Finally, Barclays assumed coverage on MacroGenics in a research report on Wednesday, September 17th. They issued an “overweight” rating and a $3.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $3.60.

MacroGenics Stock Performance

NASDAQ MGNX opened at $1.44 on Monday. The stock has a market capitalization of $91.02 million, a P/E ratio of -2.53 and a beta of 1.55. MacroGenics has a 1 year low of $0.99 and a 1 year high of $5.10. The business’s fifty day moving average is $1.72 and its two-hundred day moving average is $1.60.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.02. The company had revenue of $22.24 million for the quarter, compared to analysts’ expectations of $28.06 million. MacroGenics had a negative return on equity of 40.24% and a negative net margin of 21.99%. On average, research analysts forecast that MacroGenics will post -1.06 earnings per share for the current year.

Insider Buying and Selling at MacroGenics

In other MacroGenics news, Director William K. Heiden purchased 50,500 shares of the business’s stock in a transaction dated Tuesday, August 19th. The shares were acquired at an average price of $1.52 per share, for a total transaction of $76,760.00. Following the acquisition, the director owned 61,500 shares of the company’s stock, valued at $93,480. This trade represents a 459.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 13.00% of the company’s stock.

Institutional Investors Weigh In On MacroGenics

A number of large investors have recently bought and sold shares of MGNX. SG Americas Securities LLC lifted its position in MacroGenics by 55.9% during the 3rd quarter. SG Americas Securities LLC now owns 17,179 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 6,161 shares during the last quarter. Cresset Asset Management LLC lifted its position in MacroGenics by 52.3% during the 2nd quarter. Cresset Asset Management LLC now owns 26,720 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 9,172 shares during the last quarter. State of Wyoming lifted its position in MacroGenics by 41.8% during the 2nd quarter. State of Wyoming now owns 31,557 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 9,295 shares during the last quarter. XML Financial LLC lifted its position in MacroGenics by 68.7% during the 2nd quarter. XML Financial LLC now owns 32,336 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13,167 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in MacroGenics by 16.1% during the 2nd quarter. Bridgeway Capital Management LLC now owns 133,700 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 18,500 shares during the last quarter. 96.89% of the stock is currently owned by institutional investors.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.